Mina Nikanjam Selected Research

Mina Nikanjam Research Topics

Disease

24	Neoplasms (Cancer) 05/2024 - 01/2007
2	Acquired Immunodeficiency Syndrome (AIDS) 12/2023 - 12/2012
2	Melanoma (Melanoma, Malignant) 08/2022 - 01/2021
2	Castleman Disease (Castleman's Disease) 07/2020 - 11/2019
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018 - 01/2017
2	HIV Infections (HIV Infection) 12/2012 - 10/2012
2	Glioblastoma (Glioblastoma Multiforme) 12/2007 - 01/2007
1	Lung Neoplasms (Lung Cancer) 01/2024
1	Circulating Neoplastic Cells 12/2022
1	Tuberculosis (Tuberculoses) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Fatigue 07/2020
1	Lung Diseases (Lung Disease) 07/2020
1	Fever (Fevers) 07/2020
1	POEMS Syndrome (Syndrome, POEMS) 07/2020
1	Cough 07/2020
1	Pneumonia (Pneumonitis) 07/2020
1	Infections 07/2020
1	Renal Insufficiency (Renal Failure) 11/2018
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Hodgkin Disease (Hodgkin's Disease) 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Leukemia 01/2017
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2017

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2017
4	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2020
4	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2020
3	Circulating Tumor DNAIBA 12/2022 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 01/2021
2	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2020
2	Cell-Free Nucleic AcidsIBA 12/2022 - 06/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 01/2020
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2020 - 01/2017
2	Reverse Transcriptase InhibitorsIBA 12/2012 - 10/2012
2	oxidized low density lipoproteinIBA 12/2007 - 01/2007
2	LDL Receptors (LDL Receptor)IBA 12/2007 - 01/2007
2	LDL Lipoproteins (beta Lipoproteins)IBA 12/2007 - 01/2007
1	AntibodiesIBA 05/2024
1	Janus Kinase InhibitorsIBA 05/2024
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 05/2024
1	Agammaglobulinaemia Tyrosine KinaseIBA 05/2024
1	LigandsIBA 01/2024
1	TabletsIBA 12/2023
1	palbociclibIBA 02/2023
1	trametinibIBA 02/2023
1	Everolimus FDA Link 02/2023
1	hydrogen sulfite (bisulfite)IBA 12/2022
1	EmulsionsIBA 12/2022
1	NivolumabIBA 08/2022
1	Interleukin-2 (IL2)IBA 08/2022
1	efavirenz (Sustiva)FDA Link 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	PlatinumIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2020
1	Levofloxacin (Levaquin)FDA Link 07/2020
1	tocilizumab (atlizumab)FDA Link 07/2020
1	siltuximabIBA 07/2020
1	CytokinesIBA 07/2020
1	Interleukin-6 (Interleukin 6)IBA 07/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2020
1	Chimeric Antigen ReceptorsIBA 06/2020
1	VaccinesIBA 06/2020
1	ThymidineIBA 01/2020
1	GuanineIBA 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 01/2020
1	MethyltransferasesIBA 01/2020
1	Thymidylate SynthaseIBA 01/2020
1	TubulinIBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 01/2020
1	taxaneIBA 01/2020
1	mesoglycanIBA 01/2020
1	B7-H1 AntigenIBA 01/2020
1	AlbuminsIBA 11/2019
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2018
1	Vincristine (Oncovin)FDA LinkGeneric 01/2018
1	CPX-351IBA 01/2018
1	CreatinineIBA 01/2018
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2018
1	AzolesIBA 01/2018
1	BilirubinIBA 01/2018
1	Deoxycytidine KinaseIBA 01/2017
1	Drug CombinationsIBA 01/2017
1	NucleotidesIBA 01/2017
1	Cytotoxins (Cytolysins)IBA 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	EnzymesIBA 01/2017
1	Lamivudine (Epivir)FDA Link 12/2012

Therapy/Procedure

14	Therapeutics 02/2023 - 01/2018
5	Immunotherapy 12/2022 - 01/2017
4	Drug Therapy (Chemotherapy) 12/2022 - 01/2020
2	Precision Medicine 06/2020 - 03/2016
2	Highly Active Antiretroviral Therapy (HAART) 12/2012 - 10/2012
1	Secondary Prevention 10/2021
1	Aftercare (After-Treatment) 07/2020
1	Oral Administration 01/2020
1	Drug Tapering 11/2018